Preliminary research suggests that NG101, a drug from Neurogastrx, may lower the risk of nausea and vomiting in people taking semaglutide.
A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.
New research shows that substantially more Americans would qualify as being obese using new diagnostic criteria released this year.
Semaglutide and tirzepatide are among 20 new additions to the WHO's list of essential medicines.
In new Phase III trial data released Tuesday, people taking orforglipron lost substantially more weight than people taking a placebo.
